Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

By Zacks7 days ago

The worlds largest economy has started to witness a decline in the number of new coronavirus cases. In fact, the seven-day average of daily cases dropped to under 50,000, down 17% from the previous week (as of May 1), per a CNBC article. There has been a decline in the number of hospitalizations as well along with a decreasing death toll from coronavirus infections.

In fact, former U.S. FDA commissioner Scott Gottlieb is predicting a relatively quiet summer when it comes to coronavirus spread, as mentioned in a CNBC article. Going by the same article, he has said on CBS News that look, the situation in the U.S. continues to improve, and I think in the coming weeks we are going to see an acceleration in the decline in cases.

AD

A large COVID-19 vaccination drive has buoyed hopes of faster U.S. economic reopening of non-essential businesses and the return to normalcy. Strengthening the optimism, the United States has administered around 200 million doses of vaccines under 100 days of Biden administration, per a CNN report. According to the U.S. Centers for Disease Control and Prevention (CDC), more than half of American adults have received at least one vaccine dose, per a Reuters article. In such a scenario, lets take a look at some top coronavirus vaccine stories of April.

Novavax Close to Receiving Vaccine Authorization

Novavax NVAX is a formidable name on the list of companies which are developing a COVID-19 vaccine. The latest buzz around the vaccine developer is that it might receive authorization for COVID-19 vaccine in the United States. According to areport by Politico, there is hope that the Novavax vaccine will boost supplies, as both safety and production issues weigh on the Johnson & Johnson JNJ and AstraZeneca AZN shots.

Earlier, the companys had informed that its coronavirus vaccine candidate delivered final efficacy of 96.4% in a pivotal Phase 3 trial in the U.K., against mild, moderate and severe diseases caused by the original COVID-19 strain.

Continue read on nasdaq.com